ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

House, Senate Must Resolve Major Differences In Authorization Bills

September 12, 1980

Publications: The Cigarette Papers Available On the Web

September 27, 1996

Rare Lung Disease Raises Risk Of Meningiomas

October 26, 2001

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012

Raymond Weiss Reviews Confidential Report on I-ELCAP

April 29, 2011

Bristol-Myers Runs Afoul Of FDA In Attempt To Distribute Chapters of Oncology Textbook

June 19, 1992